Straits Times Index
3,292.93 -3.96 (-0.12%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,475.92 +268.79 (+1.48%) FTSE 100
8,213.49 +41.34 (+0.51%) Bitcoin USD
64,058.39 +1,228.15 (+1.95%) CMC Crypto 200
1,359.39 +82.41 (+6.45%)
Eli Lilly and Company (LLY.MX)
| Previous close | 12,871.00 |
| Open | 12,734.00 |
| Bid | 12,477.01 x 100 |
| Ask | 14,699.97 x 10000 |
| Day's range | 12,477.00 - 12,734.79 |
| 52-week range | 7,452.75 - 13,844.99 |
| Volume | |
| Avg. volume | 292 |
| Market cap | 12.183T |
| Beta (5Y monthly) | 0.37 |
| PE ratio (TTM) | 108.69 |
| EPS (TTM) | 115.24 |
| Earnings date | 30 Apr 2024 |
| Forward dividend & yield | 87.85 (0.70%) |
| Ex-dividend date | 14 Feb 2024 |
| 1y target est | N/A |
Yahoo FinanceAmgen's peek at its GLP-1 drug trial results heightens competition in obesity market
Competition is heating up in the GLP-1 space as Amgen gets closer to the finish line with its candidate.
Barrons.comAmazon Stock Is on a Roll. Here’s Why It’s on This Firm’s ‘Best Ideas List.’
Amazon reported strong first-quarter results, with revenue and operating income ahead of expectations. The company delivered operating income of $15.3 billion, above consensus of $11.3 billion, while reporting better-than-expected growth in both Amazon Web Services (+17.2% year over year versus Street +15%) and advertising (+24.3% Y/Y versus Street +23.5%). Amazon has now reported operating income above the high end of its guidance range for five consecutive quarters, and the company has a number of drivers for further margin expansion in place, including continued cost efficiencies within its fulfillment network as well as the ongoing mix shift toward higher-margin AWS and advertising revenue.
ZacksAmgen (AMGN) Q1 Earnings Top, Stock Up on Obesity Drug Update
Amgen (AMGN) beats first-quarter 2024 estimates for earnings and sales. Amgen is "very encouraged" by interim data from the phase II study on obesity candidate MariTide.
